Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20672068 | 0.83 | TSHR (0.35) | TSHR | |
| SCHEMBL12666551 | 0.79 | TSHR (0.38) | TSHRMEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL14376299 | 0.79 | PIN1 (0.32) | PIN1POLB | |
| SCHEMBL13230612 | 0.77 | KDM4E (0.33) | TSHRPIN1POLB | |
| SCHEMBL3482982 | 0.77 | TSHR (0.37) | TSHRMEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL19318549 | 0.76 | TSHR (0.39) | TSHRMEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL19319083 | 0.76 | TSHR (0.36) | TSHR | |
| SCHEMBL11996524 | 0.76 | TSHR (0.36) | TSHRMEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL11996531 | 0.76 | SMN1; SMN2 (0.34) | PIN1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25468552 | 0.72 | TSHR (0.33) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221334-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-8741931-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2014-06-03 | — | — | US | disclosed |
| US-20120214799-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-23 | — | — | US | disclosed |
| US-8188071-B2 | Amino substituted pyridines as potent kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110077237-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-31 | — | — | US | disclosed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221334-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | TSHR 3626/4885PIN1 685/4885MEN1 1427/4885 |
| US-20120214799-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | TSHR 3626/4885PIN1 685/4885MEN1 1427/4885 |
| US-20090124602-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | TSHR 3626/4885PIN1 685/4885MEN1 1427/4885 |
| US-20110077237-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | TSHR 3626/4885PIN1 685/4885MEN1 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.